<DOC>
	<DOCNO>NCT00655148</DOCNO>
	<brief_summary>The trial parallel group , multi-centre , randomize , double blind , non-inferiority trial investigate immunogenicity safety two DTaP-IPV combination vaccine : A ) The investigational vaccine : DTaP-IPV contain IPV produce vero-cell line ( DTaP-IPVvero ) B ) The reference vaccine : DTaP-IPV contain IPV produce monkey kidney cell ( DTaP-IPVmkc ) The DTaP-IPV vaccine administer healthy infant 2 , 3½ , 5 , 16 month age concomitantly Act-HIB vaccine administer separate injection opposite thigh . Three blood sample collect 6 , 16 17 month age . Sera analyzed antibody diphtheria , tetanus , pertussis , polio prp .</brief_summary>
	<brief_title>Safety Immunogenicity New Serum-free DTaP-IPVvero Combination Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>The parent inform trial sign consent form The subject healthy The subject age 28 49 day hepatitis B vaccination The subject birth weight ≥2500 g The subject receive hepatitis B vaccination birth The parent grant access subject 's medical record The parent likely comply instruction The subject suffers severe chronic disease The subject already immunize one dose diphtheria , tetanus , pertussis , poliomyelitis , Hib vaccines The subject know allergy one vaccine component constituent vaccine , include ActHIB® hepatitis B vaccines The subject history diphtheria , tetanus , pertussis , poliomyelitis , hepatitis B , Hib infections The subject know congenital acquire immunodeficiency The subject treatment treatment product likely modify immune response ( i.e . immunoglobulin , systemic corticosteroid , blood product , vaccine ) The subject participate another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>49 Days</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>DTaP-IPV</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>